C
Comanche Biopharma
Treating the root cause of preeclampsia and sustaining natural pregnancy
About Comanche Biopharma
Comanche Biopharma is a biopharmaceutical startup that is focused on transforming the treatment of preeclampsia, a potentially dangerous pregnancy complication characterized by high blood pressure. They are developing a new type of therapy called siRNA, which stands for small interfering RNA. This therapy works by interfering with the expression of certain genes, which can help to control or prevent certain diseases. In this case, the therapy is being used to help manage preeclampsia.
Read full description
The company's main goal is to reduce the risks associated with pregnancy and premature birth by providing a safe and sustainable way to maintain pregnancy. Their target market is pregnant women worldwide who are at risk of developing preeclampsia.
Comanche Biopharma operates in the biopharmaceutical industry, which involves the development and sale of medical drugs. Their business model revolves around the research, development, and eventual sale of their siRNA therapy. The company generates revenue through the sale of this therapy to healthcare providers who then administer it to patients.
In terms of financial analysis, the company's potential for growth and profitability is tied to the successful development and approval of their siRNA therapy. If the therapy proves to be effective and safe in clinical trials, it could potentially be a game-changer in the treatment of preeclampsia, leading to significant revenue for the company.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Concord, United States
- Employees
- 33
- Open positions
- 1
- Dealroom signal
- 90.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Femtech, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Comanche Biopharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2024 | $75M | $300M | Atlas Venture · F-Prime · Lilly Asia Ventures · Longview Healthcare Ventures | ↗ |
| EARLY VCOther financing | May 2023 | $36M | $144M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Comanche Biopharma is 3K monthly website visits, up 50% over the last three months. Comanche Biopharma's team grew 17.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
NEA
Atlas Venture
F-Prime
Lilly Asia Ventures- LVLongview Healthcare Ventures
GV
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Comanche Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Comanche Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.